Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ioannis, Xynos"'
Autor:
Yuko Kitagawa, Akira Takazawa, Yasuhiro Matsumura, Ioannis Xynos, Eva Holtved, Chih-Hung Hsu, Sung-Bae Kim, Yutaro Kubota, Chueh-Chuan Yen, Yuichiro Doki, Yasuo Hamamoto, Myung-Ju Ahn, Shigenori Kadowaki, Keisho Chin, Chen-Yuan Lin, Masanobu Takahashi, Byoung Chul Cho, Ken Kato, Morihito Okada
Supplementary Data from Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::012c9054275c23855ab7b1aee7171098
https://doi.org/10.1158/1078-0432.22483407
https://doi.org/10.1158/1078-0432.22483407
Autor:
Yuko Kitagawa, Akira Takazawa, Yasuhiro Matsumura, Ioannis Xynos, Eva Holtved, Chih-Hung Hsu, Sung-Bae Kim, Yutaro Kubota, Chueh-Chuan Yen, Yuichiro Doki, Yasuo Hamamoto, Myung-Ju Ahn, Shigenori Kadowaki, Keisho Chin, Chen-Yuan Lin, Masanobu Takahashi, Byoung Chul Cho, Ken Kato, Morihito Okada
Supplementary Table from Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59b290bf57cedce0e34902700423d351
https://doi.org/10.1158/1078-0432.22483389.v1
https://doi.org/10.1158/1078-0432.22483389.v1
Autor:
Yuko Kitagawa, Akira Takazawa, Yasuhiro Matsumura, Ioannis Xynos, Eva Holtved, Chih-Hung Hsu, Sung-Bae Kim, Yutaro Kubota, Chueh-Chuan Yen, Yuichiro Doki, Yasuo Hamamoto, Myung-Ju Ahn, Shigenori Kadowaki, Keisho Chin, Chen-Yuan Lin, Masanobu Takahashi, Byoung Chul Cho, Ken Kato, Morihito Okada
Purpose:Limited long-term data are available on immune checkpoint inhibitor use in patients with advanced esophageal squamous cell carcinoma (ESCC). We report 3-year follow-up data from our study of nivolumab versus chemotherapy (paclitaxel or doceta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70bb54d97abc90463cdf2667b9770daf
https://doi.org/10.1158/1078-0432.c.6531132.v1
https://doi.org/10.1158/1078-0432.c.6531132.v1
Autor:
Morihito Okada, Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Chen-Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki, Chueh-Chuan Yen, Yutaro Kubota, Sung-Bae Kim, Chih-Hung Hsu, Eva Holtved, Ioannis Xynos, Yasuhiro Matsumura, Akira Takazawa, Yuko Kitagawa
Publikováno v:
Clinical Cancer Research. 28:3277-3286
Purpose: Limited long-term data are available on immune checkpoint inhibitor use in patients with advanced esophageal squamous cell carcinoma (ESCC). We report 3-year follow-up data from our study of nivolumab versus chemotherapy (paclitaxel or docet
Autor:
Yuichiro, Doki, Jaffer A, Ajani, Ken, Kato, Jianming, Xu, Lucjan, Wyrwicz, Satoru, Motoyama, Takashi, Ogata, Hisato, Kawakami, Chih-Hung, Hsu, Antoine, Adenis, Farid, El Hajbi, Maria, Di Bartolomeo, Maria I, Braghiroli, Eva, Holtved, Sandra A, Ostoich, Hye R, Kim, Masaki, Ueno, Wasat, Mansoor, Wen-Chi, Yang, Tianshu, Liu, John, Bridgewater, Tomoki, Makino, Ioannis, Xynos, Xuan, Liu, Ming, Lei, Kaoru, Kondo, Apurva, Patel, Joseph, Gricar, Ian, Chau, Yuko, Kitagawa, Rachna T, Shroff
Publikováno v:
Doki, Y, Ajani, J A, Kato, K, Xu, J, Wyrwicz, L, Motoyama, S, Ogata, T, Kawakami, H, Hsu, C H, Adenis, A, El Hajbi, F, Di Bartolomeo, M, Braghiroli, M I, Holtved, E, Ostoich, S A, Kim, H R, Ueno, M, Mansoor, W, Yang, W C, Liu, T, Bridgewater, J, Makino, T, Xynos, I, Liu, X, Lei, M, Kondo, K, Patel, A, Gricar, J, Chau, I, Kitagawa, Y & CheckMate 648 Trial Investigators 2022, ' Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma ', The New England Journal of Medicine, vol. 386, no. 5, pp. 449-462 . https://doi.org/10.1056/NEJMoa2111380
BACKGROUND: First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esoph
Autor:
Masanobu Takahashi, Sung Bae Kim, Yutaro Kubota, Yuko Kitagawa, Morihito Okada, Chen Yuan Lin, Eva Holtved, Chueh Chuan Yen, Yasuo Hamamoto, Mamoru Kodani, Ken Kato, Ioannis Xynos, Chih-Hung Hsu, Myung-Ju Ahn, Yuichiro Doki, Keisho Chin, Shigenori Kadowaki, Byoung Chul Cho
Publikováno v:
Kato, K, Cho, B C, Takahashi, M, Okada, M, Lin, C Y, Chin, K, Kadowaki, S, Ahn, M J, Hamamoto, Y, Doki, Y, Yen, C C, Kubota, Y, Kim, S B, Hsu, C H, Holtved, E, Xynos, I, Kodani, M & Kitagawa, Y 2019, ' Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3) : a multicentre, randomised, open-label, phase 3 trial ', The Lancet Oncology, vol. 20, no. 11, pp. 1506-1517 . https://doi.org/10.1016/S1470-2045(19)30626-6
Background: Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival prospects. We report the final analysis from our study of the immune checkpoint PD-1 inhibitor nivolumab versus chemotherapy in pat
Autor:
Chueh-Chuan Yen, Eva Holtved, Keisho Chin, Shigenori Kadowaki, Chih-Hung Hsu, Yuko Kitagawa, Myung-Ju Ahn, Yasuo Hamamoto, Yasuhiro Matsumura, Yuichiro Doki, Yutaro Kubota, Byoung Chul Cho, Akira Takazawa, Sung-Bae Kim, Ken Kato, Ioannis Xynos, Masanobu Takahashi, Morihito Okada, Chen Yuan Lin
Publikováno v:
Chin, K, Kato, K, Cho, B C, Takahashi, M, Okada, M, Lin, C-Y, Kadowaki, S, Ahn, M-J, Hamamoto, Y, Doki, Y, Yen, C-C, Kubota, Y, Kim, S-B, Hsu, C-H, Holtved, E, Xynos, I, Matsumura, Y, Takazawa, A & Kitagawa, Y 2021, ' Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy ', Journal of Clinical Oncology, vol. 39, no. Suppl. 3, pp. 204-204 . < https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.204 >
204 Background: Previous results from the ATTRACTION-3 phase 3 trial demonstrated a significant improvement in overall survival and a favorable safety profile compared with taxane chemotherapy (CT) in previously-treated ESCC patients. To our knowledg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afe2593cb4149913be8b9e3feaa02bf7
https://portal.findresearcher.sdu.dk/da/publications/154ce1d5-2ee2-461e-b5cc-3c172f7ebb41
https://portal.findresearcher.sdu.dk/da/publications/154ce1d5-2ee2-461e-b5cc-3c172f7ebb41
Autor:
Eva Holtved, Xuan Liu, Chih-Hung Hsu, Hisato Kawakami, Ming Lei, Takashi Ogata, Antoine Adenis, Yuko Kitagawa, Yuichiro Doki, Jaffer A. Ajani, Lucjan Wyrwicz, Maria Ignez Braghiroli, Satoru Motoyama, Kaoru Kondo, Ioannis Xynos, Ken Kato, Farid El Hajbi, Ian Chau, Jianming Xu, Maria Di Bartolomeo
Publikováno v:
Journal of Clinical Oncology. 39:LBA4001-LBA4001
LBA4001 Background: NIVO demonstrated superior overall survival (OS) vs chemo in previously treated patients (pts) with ESCC (ATTRACTION-3). We report OS and progression-free survival (PFS) from CheckMate 648, the first global phase III study to eval
Autor:
Ioannis Xynos, Ken Kato, Ian Chau, Jaffer A. Ajani, Yuko Kitagawa, Agnes Balogh, Yuichiro Doki
Publikováno v:
Journal of Clinical Oncology. 36:TPS193-TPS193
TPS193 Background: Esophageal cancer (EC) is the sixth most common cause of cancer-related death worldwide, with a 5-y survival rate of 5%–8% in pts with metastatic disease. First–line platinum-based doublet chemotherapy (CTX) provides a modest s
Autor:
Luc Thomas, Ioannis Xynos, Caroline Dutriaux, Sarah Williams, Rainer Kunstfeld, Alberto Fittipaldo, Jean-Jacques Grob, Nicole Basset-Seguin, Bernard Guillot, Lisa Licitra, Laurent Mortier, Thomas Jouary, Nicolas Meyer, Brigitte Dréno, Kate Fife, Reinhard Dummer, Johan Hansson, D. Scott Ernst, Axel Hauschild, Paolo A. Ascierto
Publikováno v:
Lancet Oncology
Lancet Oncology, Elsevier, 2015, 16 (6), pp.729-736. ⟨10.1016/S1470-2045(15)70198-1⟩
Lancet Oncology, Elsevier, 2015, 16 (6), pp.729-736. ⟨10.1016/S1470-2045(15)70198-1⟩
International audience; BACKGROUND:The Hedgehog pathway inhibitor vismodegib has shown clinical benefit in patients with advanced basal cell carcinoma and is approved for treatment of patients with advanced basal cell carcinoma for whom surgery is in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b7a66e99a21db5d838836e3f4eb6434
https://doi.org/10.5167/uzh-112967
https://doi.org/10.5167/uzh-112967